Calò Lorenzo A, Ravarotto Verdiana, Simioni Francesca, Naso Elena, Marchini Francesco, Bonfante Luciana, Furian Lucrezia, Rigotti Paolo
Department of Medicine, Nephrology, Padova, Italy.
Department of Surgery, Renal and Pancreas Transplant Unit, University of Padova, Padova, Italy.
Kidney Blood Press Res. 2017;42(4):676-685. doi: 10.1159/000483023. Epub 2017 Oct 16.
Post-transplant hypertension is a common occurrence during treatment with calcineurin inhibitors (CNIs) in kidney transplant population. The pathogenesis of vasoconstriction induced by CNIs involves vascular tone alterations and kidney sodium transport regulation. Among the factors involved a key role is played by the activation of intrarenal renin-angiotensin system with enhanced release of Angiotensin II (Ang II) and increase of oxidative stress. A common pathway between oxidative stress and hypertension induced by CNIs may be identified in the involvement of the activation of RhoA/Rho kinase pathway, key for the induction of hypertension and cardiovascular-renal remodeling, of the oxidative stress mediated increased nitric oxide (NO) metabolism and increased renal sodium retention via increased activity of thiazide-sensitive sodium chloride cotransporter (NCC) in the distal tubule. We examined literature data including those coming from our group regarding the role of oxidative stress and sodium retention in CNIs induced hypertension and their involvement in cardiovascular-renal remodeling. Based on the available data, we have provided support to the activation of RhoA/Rho kinase pathway as an important effector in the pathophysiology of CNIs induced post-transplant hypertension via activation of oxidative stress and sodium retention. Clarification of how the biochemical and molecular mechanisms that regulate the processes involved in CNIs induced post transplant hypertension work and interact, would provide further insights not only into the comprehension of the pathophysiology of CNIs induced post transplant hypertension but could also have a positive impact on the clinical ground through the identification of significant targets. Their specific pharmacologic targeting might have multiple beneficial effects on the whole cardiovascular-renal function. The demonstration that in kidney transplanted patients with CNIs induced post-transplanted hypertension, the treatment of hypertension with different antihypertensive drugs inducing a comparable blood pressure reduction but different effects for example on oxidative stress and oxidative stress related proteins and/or Rho kinase and sodium retention, could be helpful for the choice of the antihypertensive treatment in these patients which takes advantage from effects of these drugs beyond blood pressure reduction.
移植后高血压是肾移植患者使用钙调神经磷酸酶抑制剂(CNIs)治疗期间的常见现象。CNIs诱导的血管收缩的发病机制涉及血管张力改变和肾脏钠转运调节。在涉及的因素中,肾内肾素-血管紧张素系统的激活起着关键作用,血管紧张素II(Ang II)释放增加,氧化应激增强。氧化应激与CNIs诱导的高血压之间的共同途径可能在于RhoA/Rho激酶途径的激活,这是诱导高血压和心血管-肾脏重塑的关键,氧化应激介导的一氧化氮(NO)代谢增加以及通过远端小管中噻嗪类敏感的氯化钠共转运体(NCC)活性增加导致肾脏钠潴留增加。我们研究了文献数据,包括来自我们团队的关于氧化应激和钠潴留在CNIs诱导的高血压中的作用及其在心血管-肾脏重塑中的参与的数据。基于现有数据,我们支持RhoA/Rho激酶途径的激活是CNIs诱导的移植后高血压病理生理学中的重要效应器,其通过激活氧化应激和钠潴留发挥作用。阐明调节CNIs诱导的移植后高血压所涉及过程的生化和分子机制如何工作及相互作用,不仅能进一步深入理解CNIs诱导的移植后高血压的病理生理学,还可能通过识别重要靶点对临床产生积极影响。它们的特异性药理靶向可能对整个心血管-肾脏功能产生多种有益作用。证明在患有CNIs诱导的移植后高血压的肾移植患者中,使用不同降压药物治疗高血压,这些药物可诱导相当的血压降低,但对氧化应激、氧化应激相关蛋白和/或Rho激酶以及钠潴留具有不同影响,这可能有助于选择这些患者的降压治疗,该治疗可从这些药物除降压之外的作用中获益。